Needle-free Injection technology has evolved significantly over the last 50 years and is now accepted in many routine immunization settings as a safe and effective vaccine delivery method. Disposable syringe jet injectors are now being used for the delivery of vaccines to eradicate polio, MMR, and influenza, and are showing promising results in vaccine clinical…
The Lancet recently published a study that demonstrates that the delivery of a Zika virus vaccine with the PharmaJet Stratis Needle-free Jet injector resulted in a higher immune response as compared with administration via needle and syringe.
Administration of intradermal fractional dose of inactivated poliovirus vaccine (fIPV) has proven to be safe and immunogenic; however, intradermal injection using needle and syringe is technically difficult and requires trained personnel.
Polio is a crippling and potentially fatal infectious disease, mainly affecting children under five years old, and there is no cure. It is estimated that less than half the amount of vaccine is available to support the global demand, and this shortage is anticipated to continue for years to come.
GOLDEN, Colo. — Dec. 19, 2017 — PharmaJet, the maker of innovative, needle-free injection technology, announced that Invectys, a French-based biopharmaceutical company, received US FDA approval to proceed with a phase II clinical trial of its therapeutic cancer vaccine, INVAC-1, using the PharmaJet needle-free injection system.
GOLDEN, Colo. – Dec. 5, 2017 – PharmaJet® Inc., the maker of needle-free injection technology, announced today that the first ever human clinical study of an mRNA rabies vaccine successfully showed immunogenicity when administered with their needle-free injection devices.
The polio eradication endgame strategic plan calls for the sequential removal of Sabin poliovirus serotypes from the trivalent oral poliovirus vaccine (tOPV), starting with type 2, and the introduction of ≥1 dose of inactivated poliovirus vaccine (IPV), to maintain an immunity base against poliovirus type 2.
GOLDEN, Colo. – Aug. 29, 2017 – PharmaJet® Inc., the maker of needle-free injection technology, today announced that shipping has begun for the quadrivalent influenza vaccine for needle-free delivery with the PharmaJet Stratis® device for the 2017-18 influenza season.
ONdrugDELIVERY publishes PharmaJet Study
Offering needle-free technology in a workplace influenza immunization program has the potential to help address an unmet need for increasing workplace health immunization rates.